Live Breaking News & Updates on Merck Vaxneuvance

Stay updated with breaking news from Merck vaxneuvance. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pneumococcal 15-Valent Conjugate Vaccine Approved for Pediatric Use

The FDA has expanded the approval of Vaxneuvance (pneumococcal 15-valent conjugate vaccine) to include 6 weeks through 17 years of age. ....

Eliav Barr , Merck Vaxneuvance , Merck Research Laboratories , Drug Administration , Biologics License Application , Merck Research , Accessed June ,